Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer
12:47pm, Tuesday, 06'th Sep 2022
AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer
AstraZeneca: Buy On The Dip
10:37pm, Monday, 05'th Sep 2022
AstraZeneca's stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively b
AstraZeneca wins injunction preventing former executive from joining GSK
10:55am, Thursday, 01'st Sep 2022
AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge. Having recently left A
AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment
12:03pm, Wednesday, 31'st Aug 2022
AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.
U.S. plans to move COVID vaccines, treatments to private markets in 2023
06:10pm, Tuesday, 30'th Aug 2022
The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Hea
AstraZeneca successfully used to treat heart failure
04:11am, Tuesday, 30'th Aug 2022
A diabetes drug developed by AstraZeneca PLC (LSE:AZN) has shown great promise in treating people with heart failure. The use of Farxiga led to ‘significantly lower risks' of hospitalisation and dea
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs
01:33pm, Thursday, 25'th Aug 2022
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
Thai king's medical firm reports record profit after vaccine deal with AstraZeneca
05:15am, Thursday, 25'th Aug 2022
Thai drugmaker Siam Bioscience, owned by the country's king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc's COVID-19 vaccine, government data show
2 Top Biotech Stocks to Buy for the Long Haul
08:40am, Wednesday, 24'th Aug 2022
Both companies have outperformed the market over the past few decades.
AstraZeneca's Soriot warns new U.S. drug price law will hurt innovation
09:44am, Tuesday, 23'rd Aug 2022
AstraZeneca's chief executive Pascal Soriot warned on Tuesday new U.S. legislation capping drug prices would reduce the ability of companies to recoup their investment on developing new drugs and hurt
AstraZeneca on hunt for oncology, cardiovascular acquisitions
09:21am, Tuesday, 23'rd Aug 2022
AstraZeneca is interested in acquiring small and mid-sized companies specialising in oncology and cardiovascular treatments, Chief Executive Pascal Soriot said in a Reuters Newsmaker interview on Tues
Ups & Downs: Top Pharmaceutical Stocks Post-COVID
06:49am, Saturday, 20'th Aug 2022
Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
12:50pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
10:32am, Tuesday, 16'th Aug 2022
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Why Gilead Sciences Stock Was a 5% Winner Today
09:29pm, Monday, 15'th Aug 2022 The Motley Fool
Investors were cheered by late-stage clinical results in breast cancer patients for Trodelvy.
